FITC-Labeled Anti-Rituximab Antibodies, Mouse IgG1 (RIB-FY35c) are expressed from human 293 cells (HEK293).
Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular seive treatment during purification process.
The FITC to protein molar ratio is 1-3.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
FITC-Labeled Anti-Rituximab Antibodies, Mouse IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind FITC-Labeled Anti-Rituximab Antibodies, Mouse IgG1 (Cat. No. RIB-FY35c) with a linear range of 0.04-0.6 μg/mL (QC tested).
2e5 of Anti-CD20 (Rituximab) CAR-293 cells were stained with 100 μL of 3 μg/mL of FITC-Labeled Anti-Rituximab Antibodies, Mouse IgG1 (Cat. No. RIB-FY35c) and isotype control antibody respectively. FITC signal was used to evaluate the binding activity (QC tested).
Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids